ClinicalTrials.gg
CompletedNCT02968368AEGIS-CKDUpdated Nov 2, 2020Results posted

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

A Phase 3 interventional study of Ferric maltol and Placebo in Renal Insufficiency, Chronic and Iron-Deficiency Anemia, sponsored by Shield Therapeutics. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-02.

Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
248th of 819
167 · median 72
Started
2016
with 45 others
Phase 3
147 of 988
13 open now
Registered
452nd of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 248th largest by enrollment of the 819 interventional ones that give a count, is one of 46 that started in 2016, is one of 147 in phase 3, and was the 452nd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD

03

Conditions studied

  • Renal Insufficiency, Chronic
  • Iron-Deficiency Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved information sheet and consent form. Must sign and date the and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations prior to any study mandated procedure.
  2. Willing and able to comply with study requirements.
  3. Age ≥ 18 years at the time of informed consent.
  4. A current diagnosis of CKD with an estimated (eGFR) of \<60 mL/min/1.73m2 and ≥15 mL/min/1.73m2, as calculated using the abbreviated version of the Modified Diet in Renal Disease equation (MDRD) assessed via screening laboratory results.
  5. Iron deficiency anemia defined by the following criteria assessed via screening laboratory results:

    1. \<11.0g/dL and ≥8.0g/dL
    2. AND ferritin \<250ng/mL with a Transferrin saturation (TSAT) \<25% OR ferritin \<500ng/mL with a TSAT of \<15%
  6. Female subjects of (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), complete sexual abstinence, a vasectomized partner and oral contraceptive medications. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or (defined as no menstrual period within 1 year of screening) are also allowed to participate.

Exclusion criteria

Exclusion Criteria:

  1. Anemia due to any cause other than iron deficiency, including, but not limited to:

    1. Untreated or untreatable severe malabsorption syndrome.
    2. Myelosuppression use (permitted if taken at a stable dose and frequency for at least 12 weeks prior to randomization and are expected to stay stable throughout the double-blind treatment period so long as there is no clinical evidence of the myelosuppression contributing to the subject's anemia).
  2. Administration with any of the following prior to randomization:

    1. IV iron injection within the previous 4 weeks or administration of intramuscular or depot iron preparation within the previous 12 weeks.
    2. Single agent oral iron supplementation, taken specifically to treat anemia (e.g. ferrous sulfate, fumarate and gluconate) within the previous 2 weeks. Multivitamins are permitted.
    3. Use if ferric citrate and sucroferric oxyhydroxide within the previous 1 week.
    4. ESAs within the previous 4 weeks
    5. Blood transfusion or donation within the previous 12 weeks.
    6. Dimercaprol or cloramphenicol within the previous 7 days.
    7. Current use of methyldopa.
  3. Currently receiving dialysis or initiation of dialysis is considered likely during the study.
  4. Renal transplant within 12 months prior to randomization or is considered likely during the study.
  5. Known or allergy to the active substance or of ferric maltol or placebo capsules.
  6. for treatment with iron preparations, e.g. hemochromatosis, chronic hemolytic disease, sideroblastic anemia, thalassemia, or lead intoxication induced anemia.
  7. Impaired liver function as indicated by (ALT) or aspartate transaminase (AST) > 3 times the as assessed via screening laboratory results.
  8. vitamin B12 or folic acid deficiency as determined by the screening laboratory results (retest following at least 2 weeks of starting treatment with vitamin B12 or folate replacement is permitted).
  9. Pregnant or breast feeding.
  10. Concomitant medical conditions with significant active bleeding likely to initiate or prolong anemia; for example coagulation disorders or recurrent GI bleeding.
  11. Scheduled or expected major surgery during the course of the study. (Minor surgeries not associated with significant blood loss, in the Investigator's judgement, are permitted e.g. surgery related to fistulae or vascular access, minor dental extractions, incision and drainage of abscess or simple excisions).
  12. Participation in any other interventional clinical study within 30 days prior to screening.
  13. Cardiovascular, liver, renal, hematologic, psychiatric, neurologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject.
  14. Any other unspecified reason that, in the opinion of the Investigator or the Sponsor make the subject unsuitable for enrolment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    Oral ferric maltol

    30mg capsules BID

    Drug: Ferric maltol

  • Placebo comparator
    Oral placebo

    Matching placebo capsules BID

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Hb Concentration From Baseline to Week 16

    Change in hemoglobin concentration from baseline to Week 16.

    Time frame: 16 weeks

Secondary outcomes

  1. Number of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16

    Number of subjects that achieve an increase in Hemoglobin concentration of ≥1 g/dL at Week 16

    Time frame: 16 weeks

  2. Number of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16

    Number of subjects that achieve a Hemoglobin concentration of ≥11 g/dL at week 16

    Time frame: 16 weeks

  3. Change in Hb Concentration From Baseline to Week 8

    Change in Hemoglobin concentration from baseline to Week 8

    Time frame: 8 weeks

  4. Number of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 16

    Number of subjects that achieve an increase in Hemoglobin concentration of ≥2 g/dL at Week 16

    Time frame: 16 weeks

  5. Changes in Ferritin From Baseline to Week 16

    Changes in iron parameter - ferritin - from baseline to week 16

    Time frame: baseline to week 16

  6. Number of Participants With (TEAEs)

    Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Week 16

  7. Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)

    Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the double blind phase

    Time frame: Week 16

  8. Changes in TSAT From Baseline to Week 16

    Changes in iron parameters - TSAT - from baseline to week 16

    Time frame: baseline to week 16

  9. Changes in Iron Parameter From Baseline to Week 16

    Changes in iron parameters - serum iron - from baseline to week 16

    Time frame: from baseline to week 16

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Number of Participants with Treatment-Emergent Adverse Events (TEAEs) during the open label phase

    Time frame: Week 52

  11. Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)

    Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the open label phase

    Time frame: Week 52

07

Results

Posted May 1, 2020

Participant flow

Double Blind Phase
Participant flow — Double Blind Phase
MilestoneOral Ferric MaltolOral Placebo
Started11156
Completed9039
Not completed2117
Open Label Phase
Participant flow — Open Label Phase
MilestoneOral Ferric MaltolOral Placebo
Started8639
Completed6725
Not completed1914

Outcome measures

PrimaryChange in Hb Concentration From Baseline to Week 16

Change in hemoglobin concentration from baseline to Week 16.

Time frame:
16 weeks
Reported as:
Least squares mean · g/dl
Change in Hb Concentration From Baseline to Week 16
g/dlOral Ferric MaltolOral Placebo
Change in Hb Concentration From Baseline to Week 160.50 ± 0.122-0.02 ± 0.165
Statistical analysis
  • Oral Ferric Maltol vs Oral Placebo · ANCOVA · p = 0.0149 · Mean difference (final values): 0.52 · 95% CI 0.102 to 0.930
SecondaryNumber of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16

Number of subjects that achieve an increase in Hemoglobin concentration of ≥1 g/dL at Week 16

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16
ParticipantsOral Ferric MaltolOral Placebo
Number of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16225
SecondaryNumber of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16

Number of subjects that achieve a Hemoglobin concentration of ≥11 g/dL at week 16

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16
ParticipantsOral Ferric MaltolOral Placebo
Number of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16307
SecondaryChange in Hb Concentration From Baseline to Week 8

Change in Hemoglobin concentration from baseline to Week 8

Time frame:
8 weeks
Reported as:
Mean · g/dl
Change in Hb Concentration From Baseline to Week 8
g/dlOral Ferric MaltolOral Placebo
Change in Hb Concentration From Baseline to Week 80.53 ± 0.9010.00 ± 0.909
SecondaryNumber of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 16

Number of subjects that achieve an increase in Hemoglobin concentration of ≥2 g/dL at Week 16

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 16
ParticipantsOral Ferric MaltolOral Placebo
Number of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 1670
SecondaryChanges in Ferritin From Baseline to Week 16

Changes in iron parameter - ferritin - from baseline to week 16

Time frame:
baseline to week 16
Reported as:
Least squares mean · ug/l
Changes in Ferritin From Baseline to Week 16
ug/lOral Ferric MaltolOral Placebo
Changes in Ferritin From Baseline to Week 1633.13 ± 6.166-5.90 ± 9.137
Statistical analysis
  • Oral Ferric Maltol vs Oral Placebo · ANCOVA · p = 0.0006 · Mean difference (final values): 39.03 · 95% CI 17.070 to 60.992
SecondaryNumber of Participants With (TEAEs)

Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With (TEAEs)
ParticipantsOral Ferric MaltolOral Placebo
Number of Participants With (TEAEs)7542
SecondaryNumber of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)

Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the double blind phase

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsOral Ferric MaltolOral Placebo
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)2312
SecondaryChanges in TSAT From Baseline to Week 16

Changes in iron parameters - TSAT - from baseline to week 16

Time frame:
baseline to week 16
Reported as:
Least squares mean · TSAT (%)
Changes in TSAT From Baseline to Week 16
TSAT (%)Oral Ferric MaltolOral Placebo
Changes in TSAT From Baseline to Week 164.32 ± 0.719-0.15 ± 1.060
Statistical analysis
  • Oral Ferric Maltol vs Oral Placebo · ANCOVA · p = 0.0007 · Mean difference (final values): 4.46 · 95% CI 1.928 to 7.001
SecondaryChanges in Iron Parameter From Baseline to Week 16

Changes in iron parameters - serum iron - from baseline to week 16

Time frame:
from baseline to week 16
Reported as:
Least squares mean · umol/l
Changes in Iron Parameter From Baseline to Week 16
umol/lOral Ferric MaltolOral Placebo
Changes in Iron Parameter From Baseline to Week 161.87 ± 0.3970.01 ± 0.586
Statistical analysis
  • Oral Ferric Maltol vs Oral Placebo · ANCOVA · p = 0.0098 · Mean difference (final values): 1.86 · 95% CI 0.457 to 3.261
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Number of Participants with Treatment-Emergent Adverse Events (TEAEs) during the open label phase

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsOral Ferric MaltolOral Placebo
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)7635
SecondaryNumber of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)

Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the open label phase

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsOral Ferric MaltolOral Placebo
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)279

Adverse events

Collected over 16 week double blind phase. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Ferric Maltol DB75/111 (67.6%)23/111 (20.7%)75/111 (67.6%)
Oral Placebo DB42/56 (75%)12/56 (21.4%)42/56 (75%)
Oral Ferric Maltol OL76/86 (88.4%)27/86 (31.4%)76/86 (88.4%)
Oral Placebo OL35/39 (89.7%)9/39 (23.1%)35/39 (89.7%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventOral Ferric Maltol DBOral Placebo DBOral Ferric Maltol OLOral Placebo OL
Cardiac failure congestiveCardiac disorders1/1110/561/862/39
Acute kidney injuryRenal and urinary disorders1/1111/561/862/39
AnemiaBlood and lymphatic system disorders0/1112/560/860/39
Angina pectorisCardiac disorders0/1111/560/861/39
HyperglycemiaMetabolism and nutrition disorders1/1110/560/861/39
HyperkalemiaMetabolism and nutrition disorders0/1111/561/861/39
Hypertensive emergencyVascular disorders1/1111/561/861/39
Mental status changesPsychiatric disorders0/1111/560/861/39
CoagulopathyBlood and lymphatic system disorders0/1110/561/861/39
Acute myocardial infarctionCardiac disorders0/1110/561/861/39
Most frequent other events
Showing 10 of 27
Most frequent other events
EventOral Ferric Maltol DBOral Placebo DBOral Ferric Maltol OLOral Placebo OL
Gastrointestinal disordersGastrointestinal disorders45/11117/5648/8618/39
Infections and infestationsInfections and infestations17/11113/5639/8619/39
Metabolism and nutrition disordersMetabolism and nutrition disorders21/11113/5625/8613/39
Respiratory, thoracic, and mediastinal disordersRespiratory, thoracic and mediastinal disorders0/1110/5619/867/39
Injury, poisoning, and procedural complicationsInjury, poisoning and procedural complications0/1110/5617/864/39
General disorders and administration site conditionsGeneral disorders0/1110/5616/865/39
Vascular disordersVascular disorders0/1110/5616/865/39
ConstipationGastrointestinal disorders9/1112/5614/865/39
Blood and lymphatic system disordersBlood and lymphatic system disorders5/1119/560/860/39
HyperkalemiaMetabolism and nutrition disorders4/1117/565/866/39

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Oral Ferric MaltolOral PlaceboTotal
<=18 years000
Between 18 and 65 years341953
>=65 years7737114
Age, Continuous
Age, Continuous(years)Oral Ferric MaltolOral PlaceboTotal
Mean68.5 ± 12.4365.2 ± 12.7967.4 ± 12.61
Sex: Female, Male
Sex: Female, Male(Participants)Oral Ferric MaltolOral PlaceboTotal
Female7839117
Male331750
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Ferric MaltolOral PlaceboTotal
Hispanic or Latino261440
Not Hispanic or Latino8442126
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Ferric MaltolOral PlaceboTotal
American Indian or Alaska Native101
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American231235
White8142123
More than one race000
Unknown or Not Reported426
Region of Enrollment
Region of Enrollment(participants)Oral Ferric MaltolOral PlaceboTotal
United States11156167
08

Study locations

27 sites
  • Peoria, Arizona, United States
  • Phoenix, Arizona, United States
  • Prescott, Arizona, United States
  • Tucson, Arizona, United States
  • La Mesa, California, United States
  • Long Beach, California, United States
  • Roseville, California, United States
  • Sacramento, California, United States
  • Denver, Colorado, United States
  • Coral Springs, Florida, United States
  • Edgewater, Florida, United States
  • Lauderdale Lakes, Florida, United States
  • Miami, Florida, United States
  • Macon, Georgia, United States
  • Shreveport, Louisiana, United States
  • Pontiac, Michigan, United States
  • Roseville, Michigan, United States
  • Las Vegas, Nevada, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Bethlehem, Pennsylvania, United States
  • Knoxville, Tennessee, United States
  • Nashville, Tennessee, United States
  • El Paso, Texas, United States
  • San Antonio, Texas, United States
  • Hampton, Virginia, United States
09

References and documents

Publications

  • Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis. 2021 Dec;78(6):846-856.e1. doi: 10.1053/j.ajkd.2021.03.020. Epub 2021 May 23. PubMed 34029682 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jan 2018, 13 months.

Results were first posted in May 2020, 2 years 3 months after primary completion.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 13 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2016
First posted
Nov 18, 2016
StartActual
Dec 1, 2016
Primary completionActual
Jan 18, 2018
CompletionActual
Oct 10, 2018
Results first posted
May 1, 2020
Last update
Nov 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02968368
Lead sponsor
Shield Therapeutics
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Dec 1, 2016
Primary completion
Jan 18, 2018
Completion
Oct 10, 2018
Results posted
May 1, 2020
Last update
Nov 2, 2020

Study contacts

Mark Sampson, MBChB
study director · Shield Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric maltol

Start the discussion